DVA Davita (DVA) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-misc health & allied services, nec · CIK 0000927066
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
309
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $639.9K priced
What the filings say about DVA
Insiders, 180 days
-$254.4M net sold
6 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-09-25
Davita insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, DAVITA INC. insiders sold a net $254.4M of stock across 75 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on May 1, 2026.
- The trade is 0.6% of the 28,697,229 shares held after it.
- No other insider sold within 30 days.
- 309 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider BERKSHIRE HATHAWAY INC sold about $36.5M of DVA on Jul 31, 2026; 309 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Jun 15, 2026.
- The trade is 4.7% of the 840,408 shares held after it.
- 1 other insider sold within 30 days.
- 309 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Rodriguez Javier sold about $8.2M of DVA on Jun 16, 2026; 1 other insider sold within 30 days and 309 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 13, 2024.
- The trade is 7.7% of the 115,649 shares held after it.
- 1 other insider sold within 30 days.
- 309 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal & Pub. Affairs Off Waters Kathleen Alyce sold about $1.9M of DVA on Jun 15, 2026; 1 other insider sold within 30 days and 309 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 13, 2024.
- The trade is 5.9% of the 109,194 shares held after it.
- 1 other insider sold within 30 days.
- 309 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal & Pub. Affairs Off Waters Kathleen Alyce sold about $1.4M of DVA on Jun 15, 2026; 1 other insider sold within 30 days and 309 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Sep 16, 2024.
- The trade is 3.4% of the 879,815 shares held after it.
- 1 other insider sold within 30 days.
- 309 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Rodriguez Javier sold about $6.3M of DVA on Jun 15, 2026; 1 other insider sold within 30 days and 309 funds added in the latest 13F quarter.75 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$254.4M over 180 days
-$36.5M over 90 days · -$219.4M of it by a 10%+ holder
below 92% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
309 funds bought in last quarter
more than 88% of Healthcare Services
Revenue
+6.5% year over year
below 60% of Healthcare Services
Margin
5.5% net margin
more than 71% of Healthcare Services
Buybacks
$377.9M repurchased, FY to 2026-06-30
more than 87% of Healthcare Services
Short interest
15.2% of the float short (float per yahoo 2026-10-26) · 6.5 days to cover · settled 2026-09-30
more than 79% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch DVA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+42.3%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns DVA: institutional holders (13F)
13F holdings, latest reported quarter
28,880,209 sh
$6.4B
2,460,987 sh
$547.5M
2,101,425 sh
$467.5M
1,601,710 sh
$356.3M
1,377,914 sh
$306.6M
Congress trades in DVA
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-09-25 · disclosed 12 days later
$1,001 - $15,000
Bought 2025-09-23 · disclosed 316 days later
$1,001 - $15,000
Sold 2025-09-23 · disclosed 316 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
DVA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
DVA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
VistaShares Target 15 Berkshire Select Income ETF
$51.4M position · as of 2026-07-31
5.2%
Leadershares Alphafactor Tactical Focused ETF
$2.2M position · as of 2026-07-31
3.5%
Hennessy Sustainable ETF
$3.1M position · as of 2026-07-31
3.4%
Aztlan Global Stock Selection DM SMID ETF
$1.2M position · as of 2026-07-31
3.1%
Neuberger Quality Equity Fund
$122.8M position · as of 2026-05-31
2.9%
First Trust Health Care AlphaDEX Fund
$25.6M position · as of 2026-07-31
2.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Davita Inc. Political Action Committee (Dapac)
Cycle 2026 · $986K spent
$934.8K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Javier J. Rodriguez
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$18.2M
$18.9M
$4.4M
-3%
+13%
2024
$21.8M
$20.6M
$5.3M
+27%
-5%
2023
$6.7M
$4.8M
$6.4M
-11%
-7%
2022
$3.0M
-$86.4M
$4.2M
-36%
-12%
2021
$3.3M
-$13.1M
$4.3M
-3%
+10%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $254.4M sold by insiders over 180 days, 309 funds added last quarter. Each figure is a federal filing, dated the day it went public.
DVA financials
Revenue growth
+6.5%
XBRL, annual
Net margin
5.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$14.0B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM DVA
| FY Dec 2025 | $13.6B |
| FY Dec 2024 | $12.8B |
| FY Dec 2023 | $12.1B |
| FY Dec 2022 | $11.6B |
| FY Dec 2021 | $11.6B |
| Jun 2026 | $3.6B |
| Mar 2026 | $3.4B |
| Dec 2025 | $3.6B |
| Sep 2025 | $3.4B |
| Jun 2025 | $3.4B |
| Mar 2025 | $3.2B |
| Dec 2024 | $3.3B |
| Sep 2024 | $3.3B |
At each fiscal year end
Single quarter
Net margin, TTM
+8.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM DVA
| FY Dec 2025 | +7.9% |
| FY Dec 2024 | +9.8% |
| FY Dec 2023 | +7.9% |
| FY Dec 2022 | +6.7% |
| FY Dec 2021 | +10.4% |
| Jun 2026 | +7.5% |
| Mar 2026 | +5.8% |
| Dec 2025 | +15.6% |
| Sep 2025 | +4.4% |
| Jun 2025 | +5.9% |
| Mar 2025 | +5.1% |
| Dec 2024 | +17.4% |
| Sep 2024 | +6.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$1.6B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM DVA
| FY Dec 2025 | $1.3B |
| FY Dec 2024 | $1.5B |
| FY Dec 2023 | $1.5B |
| FY Dec 2022 | $961.1M |
| FY Dec 2021 | $1.3B |
| Jun 2026 | $320.3M |
| Mar 2026 | $218.8M |
| Dec 2025 | $395.3M |
| Sep 2025 | $675.4M |
| Jun 2025 | $203.1M |
| Mar 2025 | $36.8M |
| Dec 2024 | $377.0M |
| Sep 2024 | $671.4M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity DVA
| FY Dec 2025 | n/a |
| FY Dec 2024 | 75.76x |
| FY Dec 2023 | 7.83x |
| FY Dec 2022 | 12.20x |
| FY Dec 2021 | 11.55x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | 75.76x |
| Sep 2024 | 23.95x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.21x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt DVA
| FY Dec 2025 | 0.19x |
| FY Dec 2024 | 0.22x |
| FY Dec 2023 | 0.25x |
| FY Dec 2022 | 0.18x |
| FY Dec 2021 | 0.22x |
| Jun 2026 | 0.21x |
| Mar 2026 | 0.19x |
| Dec 2025 | 0.19x |
| Sep 2025 | 0.19x |
| Jun 2025 | 0.18x |
| Mar 2025 | 0.24x |
| Dec 2024 | 0.22x |
| Sep 2024 | 0.21x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity DVA
| FY Dec 2025 | n/a |
| FY Dec 2024 | +212.5% |
| FY Dec 2023 | +108.2% |
| FY Dec 2022 | +106.5% |
| FY Dec 2021 | +113.3% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | +874.1% |
| Mar 2025 | +356.4% |
| Dec 2024 | +212.5% |
| Sep 2024 | +137.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+6.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets DVA
| FY Dec 2025 | +6.2% |
| FY Dec 2024 | +7.3% |
| FY Dec 2023 | +5.7% |
| FY Dec 2022 | +4.6% |
| FY Dec 2021 | +7.1% |
| Jun 2026 | +6.7% |
| Mar 2026 | +6.4% |
| Dec 2025 | +6.2% |
| Sep 2025 | +6.2% |
| Jun 2025 | +6.7% |
| Mar 2025 | +6.8% |
| Dec 2024 | +7.3% |
| Sep 2024 | +6.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+17.9%
operating income after a 20.7% effective tax rate, over long-term debt only, 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital DVA
| FY Dec 2025 | +17.4% |
| FY Dec 2024 | +18.6% |
| FY Dec 2023 | +14.7% |
| FY Dec 2022 | +11.7% |
| FY Dec 2021 | +15.3% |
| Jun 2026 | +17.9% |
| Mar 2026 | +17.3% |
| Dec 2025 | +17.4% |
| Sep 2025 | +17.7% |
| Jun 2025 | +17.2% |
| Mar 2025 | +17.5% |
| Dec 2024 | +18.6% |
| Sep 2024 | +16.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+14.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed DVA
| FY Dec 2025 | +14.3% |
| FY Dec 2024 | +14.6% |
| FY Dec 2023 | +11.2% |
| FY Dec 2022 | +9.2% |
| FY Dec 2021 | +12.3% |
| Jun 2026 | +14.5% |
| Mar 2026 | +14.5% |
| Dec 2025 | +14.3% |
| Sep 2025 | +14.1% |
| Jun 2025 | +14.5% |
| Mar 2025 | +14.1% |
| Dec 2024 | +14.6% |
| Sep 2024 | +13.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
15.11x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing DVA
| FY Dec 2025 | 11.55x |
| FY Dec 2024 | 13.95x |
| FY Dec 2023 | 14.16x |
| FY Dec 2022 | 12.83x |
| FY Dec 2021 | 12.77x |
| Jun 2026 | 18.31x |
| Mar 2026 | 14.35x |
| Dec 2025 | 11.55x |
| Sep 2025 | 13.71x |
| Jun 2025 | 14.03x |
| Mar 2025 | 15.19x |
| Dec 2024 | 13.95x |
| Sep 2024 | 17.68x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$21.7B
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value DVA
| FY Dec 2025 | $17.5B |
| FY Dec 2024 | $20.6B |
| FY Dec 2023 | $17.5B |
| FY Dec 2022 | $15.2B |
| FY Dec 2021 | $19.9B |
| Jun 2026 | $24.3B |
| Mar 2026 | $20.1B |
| Dec 2025 | $17.5B |
| Sep 2025 | $19.0B |
| Jun 2025 | $20.1B |
| Mar 2025 | $21.4B |
| Dec 2024 | $20.6B |
| Sep 2024 | $21.9B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+13.7%
TTM free cash flow over market value at close 2026-10-23
FCF yield DVA
| FY Dec 2025 | +16.3% |
| FY Dec 2024 | +12.0% |
| FY Dec 2023 | +15.6% |
| FY Dec 2022 | +14.3% |
| FY Dec 2021 | +11.1% |
| Jun 2026 | +11.3% |
| Mar 2026 | +14.5% |
| Dec 2025 | +16.3% |
| Sep 2025 | +13.6% |
| Jun 2025 | +12.0% |
| Mar 2025 | +14.4% |
| Dec 2024 | +12.0% |
| Sep 2024 | +10.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.77x
P/E over trailing EPS growth of 20%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing DVA
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.31x |
| FY Dec 2023 | 0.52x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.31x |
| Jun 2026 | 0.93x |
| Mar 2026 | 2.26x |
| Dec 2025 | n/a |
| Sep 2025 | 3.03x |
| Jun 2025 | 1.73x |
| Mar 2025 | 1.05x |
| Dec 2024 | 0.31x |
| Sep 2024 | 0.43x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $13.6B | $12.8B | $12.1B | $11.6B |
| Operating income | $2.0B | $2.1B | $1.6B | $1.3B |
| Net income | $1.1B | $1.3B | $957.0M | $781.6M |
| EPS (diluted) | 9.84 | 10.73 | 7.42 | 5.85 |
| Operating cash flow | $1.9B | $2.0B | $2.1B | $1.6B |
| Cash | $676.4M | $794.9M | $380.1M | $244.1M |
| Long-term debt | $10.2B | $9.2B | $8.3B | $8.7B |
| Buybacks | $1.3B | $1.4B | $272.2M | $802.2M |
| Dividends paid | $0 | $0 | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-27
DVA Stock Sonar score 6/7 axes
Find similar shapesCompareDVA ranks highest on institutional and government (92nd percentile) and profitability (76th), and lowest on insider conviction (4th), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
DVA filings, in plain words
Are Davita insiders buying or selling DVA?
In the 180 days to 2026-10-27, Davita insiders were net sellers, a net $254.4M across purchases and sales reported on Form 4, by 6 sellers.
Have members of Congress traded DVA?
Yes, but not in the year to 2026-10-27; the latest on record is a sale by Julie Johnson dated 2025-09-25.
Read the full summary
In the 180 days to 2026-10-27, Davita insiders were net sellers of DVA, a net $254.4M across purchases and sales reported on Form 4 by 6 sellers. Most of that figure, $219.4M, came from a holder of 10% or more rather than an officer or director. None of the 11 insider sales was flagged as made under a Rule 10b5-1 plan. Members of Congress have disclosed trades in DVA, none in the last year; the latest on record is a sale by Julie Johnson dated 2025-09-25. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
